IRIS
GROSSI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.660
Totale 2.660
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.660
Totale 2.660
Salva come PNG Salva come JPEG
Città #
Genova 1.555
Rapallo 507
Genoa 361
Vado Ligure 226
Bordighera 11
Totale 2.660
Salva come PNG Salva come JPEG
Nome #
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 124
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely 109
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 97
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 95
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 95
Understanding the checkpoint blockade in lung cancer immunotherapy 89
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 86
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 86
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 81
Gefitinib treatment outcome after progression on erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) 79
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? 77
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 77
Difference in skin toxicity incidence between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 72
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 70
Exosomes: a new horizon in lung cancer 69
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 66
Vinflunine for the treatment of non-small cell lung cancer 66
Skin toxicities difference between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 64
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 63
PCSK9 is a promising prognostic marker in patients with advanced NSCLC 59
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 58
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 58
Disease stabilization as a surrogate end point in advanced non small cell lung cancer patients treated with erlotinib or gefitinib 56
Afatinib for the treatment of non-small cell lung cancer 56
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 56
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 54
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 53
Hematopoietic growth factors in lung cancer 52
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 50
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 48
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer 45
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 45
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 43
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial 43
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 43
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 40
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: Can we use enemy territory at our advantage? 40
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy” 40
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 39
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 39
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer 37
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 34
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 33
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 32
Looking for results in non-small-cell lung cancer: Is bio-chemotherapy the right answer? 30
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects 20
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 6
PCSK9 as a new player in cancer: New opportunity or red herring? 4
Totale 2.778
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.074
article - articoli 12.992
book - libri 0
conference - conferenze 1.082
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020205 0 0 0 0 14 27 40 16 20 42 40 6
2020/2021734 5 30 14 214 137 12 69 67 65 73 18 30
2021/2022527 69 16 5 28 30 53 10 118 27 64 25 82
2022/2023577 47 38 10 58 101 101 0 54 87 6 70 5
2023/2024283 8 35 7 46 21 50 23 19 14 14 2 44
2024/2025249 24 58 33 59 75 0 0 0 0 0 0 0
Totale 2.778